Pages Menu
Categories Menu

News

New Findings Highlight the Potential Utility of Pitavastatin for People Living with HIV in Support of the REPRIEVE Trial

Posted by on Apr 24, 2017 in News | 0 comments

April 24, 2017   Stemming from the INTREPID Trial, three recently published papers give credence to pitavastatin’s ability to lower cholesterol and dampen inflammation in people living with HIV. While the results demonstrate the unique effects of pitavastatin in HIV and underscore its position as a promising cardiovascular disease (CVD) prevention strategy, they also highlight the need for the REPRIEVE Trial to determine whether pitavastatin prevents cardiovascular disease events, such as heart attacks and strokes. Read more here:...

read more

REPRIEVE Featured in Article by Barbara Streisand & Dr. Anthony Fauci

Posted by on Sep 13, 2016 in News | 0 comments

In the article, “A Reprieve for Women: Embracing Inclusive Scientific Research”, Barbara Streisand and Dr. Anthony Fauci underscore REPRIEVE as a unique, well-designed study that takes sex and gender into account from recruitment to study data analysis. Click the image below to read the full article: A Reprieve For Women: Embracing Inclusive Scientific...

read more

REPRIEVE’s One Year Anniversary Featured on the PRWeb!

Posted by on Apr 14, 2016 in News | 0 comments

Check out the one year press release for REPRIEVE, the largest HIV-related cardiovascular disease clinical trial ever, featured on the PRWeb!

read more

World AIDS Day

Posted by on Dec 1, 2015 in News | 0 comments

Leadership from REPRIEVE: Randomized Trial to Prevent Vascular Events in HIV, would like to recognize World AIDS Day as a time to remember those we have lost to HIV/AIDS and also recognize the progress that has been made to help people with HIV live longer, healthier lives. For those living with HIV the outlook regarding life expectancy is more positive than ever. In fact, it is more likely that a person living with HIV in the developed world will die from a non-HIV related condition such as heart disease or cancer than an HIV-related cause. Heart disease is of particular interest right now as the risk of developing heart disease (including heart attack and stroke) is 1.5 to 2.0 times greater among people living with HIV compared to those without HIV. The REPRIEVE trial will be the largest trial focused on the prevention of heart disease as well as other non-HIV related conditions such as cancer and kidney disease. REPRIEVE will test whether a daily dose of a statin (pitavastatin) will reduce the risk of heart disease and death among HIV-infected individuals who are currently taking antiretroviral therapy and who may or may not be recommended for statins – according to the 2013 ACC/AHA guidelines. By proactively addressing these non-HIV related health issues, the REPRIEVE trial may have the potential to ensure not only longer lives for the HIV community but also to increase the quality of life among those living with HIV. REPRIEVE is currently enrolling participants at over 100 sites in the United States and abroad. For more details about this landmark trial, please visit the website at...

read more

REPRIEVE Featured in The Body

Posted by on Oct 15, 2015 in News | 0 comments

The REPRIEVE Trial is featured in The Body on a list of top clinical research topics in HIV!

read more

REPRIEVE in Recent HIV/AIDS Report Review Article!

Posted by on Aug 12, 2015 in News | 0 comments

REPRIEVE described in recently released review article on statins in HIV! Click to read!

read more

REPRIEVE Recently in Healio!

Posted by on Jul 30, 2015 in News | 0 comments

REPRIEVE likely to clarify value of statins in HIV. Click here to learn more!

read more

REPRIEVE featured in JAMA

Posted by on Jul 30, 2015 in News | 0 comments

JAMA article highlights REPRIEVE trial for studying ways to prevent HIV-Related Heart Disease! Individuals living with HIV are at increased risk of heart disease. The REPRIEVE study hopes to better understand why. Click here to read more!  

read more

REPRIEVE in POZ

Posted by on Jul 28, 2015 in News | 0 comments

REPRIEVE was recently featured online in POZ. Click here to read more!

read more

CVD Prevention Challenging as Patients with HIV Live Longer

Posted by on Jun 2, 2015 in News | 0 comments

Healio Article on how CVD prevention and treatment is becoming challenging as patients with HIV and HCV live longer. Click here to learn more!

read more